Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
No intraday reading yet this session.
Karyopharm Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Under the terms of the agreement with BMS, we are sponsoring the trial as a new arm of the STOMP Trial and BMS will supply the trial's clinical drug mezigdomide.”
FILING10-K0001193125-26-049397cik 0001503802
“We have retained the exclusive production rights and will supply finished product to FORUS for commercial use in Canada.”
FILING10-K0001193125-26-049397cik 0001503802
“License revenue included $15.0 million of revenue for the reimbursement of development related expenses from the Menarini Group ("Menarini").”
FILING10-K0001193125-26-049397cik 0001503802
“Under the terms of the Original Antengene Agreement, we received an upfront cash payment of $11.7 million in 2018.”
FILING10-K0001193125-26-049397cik 0001503802
“We received from Libo an upfront payment and a milestone payment upon completion of technology transfer and are entitled to receive development and regulatory milestones and single-digit royalties on future net sales of KPT-1200.”
FILING10-K0001193125-26-049397cik 0001503802
“Promedico received the exclusive rights to commercialize XPOVIO in the Promedico Territory and is responsible for all regulatory filings and obligations required for registering XPOVIO.”
FILING10-K0001193125-26-049397cik 0001503802
Watchlist prices, news filtered to it, and its next report on your desk.
Karyopharm Therapeutics Inc. has 1 disclosed supplier and 5 disclosed customers. Each one is named in an SEC filing, either Karyopharm Therapeutics Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
KPTI (Karyopharm Therapeutics Inc.) has 1 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: BMY +0.01%, in healthcare.